Gadolinium-Based Contrast Agents in MRIs Connected to Nephrogenic Systemic Fibrosis
Patients undergo MRIs (magnetic resonance imaging) for various reasons. Whether it’s to discover an injury that an X-ray cannot detect, or to determine the presence of cancer, MRIs are frequently used. When undergoing an MRI, technicians and physicians will turn to a contrast agent, such as Gadolinium, to help alter the images of the area being screened to improve its quality in the results.
These Gadolinium contrast agents are injected into the patients’ bloodstream prior to the MRI scan so that the MRI computer can make an accurate distinction between abnormal and normal tissue. However, once researchers discovered in 2006 that Gadolinium use directly caused nephrogenic systemic fibrosis (NSF) in patients with pre-existing kidney problems, the Food and Drug Administration (FDA) issued an official warning. It is no surprise then, that some patients have become mistrustful of MRIs.
According to the International Center for Nephrogenic Systemic Fibrosis Research, NSF, presently under peer review, is a disorder in which patients develop immense regions of hardened skin. The areas of the skin that are thickened are characterized by somewhat projecting plaques, papules, or confluent papules that may or may not increase skin deposits of mucin (protein-containing mucous), and include pigmentary alteration. Patients who suffer severe effects of the condition may experience muscle weakness, with some patients being unable to walk or completely extend the joints of their hands, arms, feet, and legs.
Those who undergo an MRI trust that they are in good hands. It is highly unacceptable for patients to suffer toxic effects from Gadolinium-based contrast agents while having an MRI. If you have contracted NSF or any other condition after undergoing an MRI in Missouri, the St. Louis injury attorneys at Page Cagle can help. Call 866-620-5757 today for a free consultation and to learn more about what can be done to help protect your legal rights.
Source reports: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152672.htm
